A Safety and Efficacy Study of Travoprost 0.004% Compared to Latanoprost 0.005% in Patients With Open-Angle Glaucoma (OAG) or Ocular Hypertension (OHT)

Completed · Phase 3

Conditions studied: Glaucoma, Open-Angle, Ocular Hypertension

In brief

The purpose of this study is to evaluate the safety and IOP-lowering efficacy of Travoprost (0.004%) compared to Latanoprost (0.005%) in patients with chronic open-angle glaucoma or ocular hypertension.

Key facts

Study ID

NCT00051142

Run by

Alcon Research

Starts

2001-02-01

Expected to finish

2004-06-01

Last updated by the study team

2008-08-05

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

• Latin America — Fort Worth, Texas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.